抗药性淋病在全球呈上升趋势,对关键抗生素的抗药性很高,尤其是在东南亚。 Drug-resistant gonorrhea is rising globally, with high resistance to key antibiotics, especially in Southeast Asia.

世界卫生组织报告称，耐药淋病病例急剧上升，2022年至2024年间，对关键抗生素首曲松和头孢克肟的耐药性分别从0.8%升至5%和1.7%至11%。 The World Health Organization reports a sharp rise in drug-resistant gonorrhea, with resistance to key antibiotics ceftriaxone and cefixime increasing from 0.8% to 5% and 1.7% to 11% between 2022 and 2024. 抗艾兹罗迈因的抗药性上升到4%,而恶丙霉素抗药性达到95%,主要在柬埔寨和越南。 Resistance to azithromycin rose to 4%, while ciprofloxacin resistance reached 95%, primarily in Cambodia and Vietnam. 来自12个国家的数据显示,有3 615例病例,大多数为中位年龄为27岁的男子,与多个伙伴和最近使用抗生素有关。 Data from 12 countries show 3,615 cases, mostly in men with a median age of 27, linked to multiple partners and recent antibiotic use. 卫生组织敦促加强全球监测、改进诊断、获得诸如Zoliflodacin等新疗法的机会以及改进报告工作,特别是在资金和数据短缺的情况下,从妇女和生殖外地点提出报告。 WHO urges stronger global surveillance, better diagnostics, access to new treatments like zoliflodacin, and improved reporting, especially from women and extragenital sites, amid funding and data gaps.